Bolt Biotherapeutics (BOLT) Restructuring Costs (2024 - 2025)
Bolt Biotherapeutics (BOLT) posted Restructuring Costs of $1.5 million for Q4 2025, up 766.67% sequentially from -$222000.0 in Q4 2024, and up 766.67% YoY from $170769.2 in Q4 2024.
Bolt Biotherapeutics (BOLT) Restructuring Costs (2024 - 2025) Analysis & Trends
Bolt Biotherapeutics has reported Restructuring Costs for 2 years, with the latest figure at $1.5 million in Q4 2025.
- Quarterly Restructuring Costs rose 766.67% year-over-year to $1.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.3 million (changed N/A YoY) and the FY2025 annual result came in at $1.5 million, down 55.73% from the prior year.
- Restructuring Costs advanced to $1.5 million in Q4 2025 per BOLT's latest filing, from -$222000.0 in the prior quarter.
- Over five years, Restructuring Costs peaked at $3.6 million in Q2 2024 and troughed at -$222000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Bolt Biotherapeutics | 5.80 Mn | 5.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.48 Mn |
| Dec 31, 2024 | -222,000.00 |
| Jun 30, 2024 | 3.57 Mn |